COMMUNIQUÉS West-GlobeNewswire

Vistin Pharma ASA: Mandatory notification of trade

23/08/2024 - 16:06

Saga Pure ASA has on 23 August 2024 purchased 300,000 shares in Vistin Pharma ASA at NOK 22,50 per share. After the transaction Saga Pure ASA has a holding of 400,000 shares, corresponding to 0.9 % ownership. Saga Pure [...]

BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.

23/08/2024 - 16:00

GRANTS, NEW MEXICO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed a letter of intent to supply its DEA-approved marijuana [...]

Wendy Vlieks Appointed as President of The Genome Partnership, Succeeding Leisa Zigman

23/08/2024 - 16:00

Experienced Communications Leader to Drive Growth and Educational Initiatives ST. LOUIS, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The Genome Partnership is pleased to announce the appointment of Wendy Vlieks, former VP of [...]

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

23/08/2024 - 15:01

Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024 Exclusive distribution agreement extended to also include Sweden and Denmark Altamira Therapeutics [...]

OKYO Pharma CEO Interview to Air on Bloomberg TV

23/08/2024 - 15:00

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye [...]

CytoDyn Engages Leading CRO For Phase II Inflammation Trial

23/08/2024 - 14:30

VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple [...]

Le KFSHRC établit de nouvelles normes mondiales en matière de technologie de RV à l’occasion de la conférence AMEE 2024

23/08/2024 - 14:15

RIYAD, Arabie saoudite, 23 août 2024 (GLOBE NEWSWIRE) -- En adoptant sans cesse de nouvelles technologies, le KFSHRC veille à ce que ses apprenants disposent des compétences et des connaissances nécessaires pour relever [...]

WORK Medical Technology Group LTD Announces Pricing of Initial Public Offering

23/08/2024 - 14:00

Hangzhou, China, Aug. 23, 2024 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (the "Company"), a supplier of medical devices in China, today announced the pricing of the initial public offering (the "Offering") [...]

European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma

23/08/2024 - 13:30

First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR 3 alterations Approval based on THOR results, showing 36 [...]

Repligen Corporation to Present at Wells Fargo Healthcare Conference

23/08/2024 - 13:30

WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo [...]

OKYO Pharma Announces Chairman Acquires Shares

23/08/2024 - 13:00

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye [...]

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

23/08/2024 - 13:00

CALGARY, Alberta, Aug. 23, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]

AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema

23/08/2024 - 13:00

Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed [...]

KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs

23/08/2024 - 11:46

RIYADH, Saudi Arabia, Aug. 23, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) solidifies its medical education and research leadership through its Academic & Training Affairs [...]

PCI Biotech: Invitation to first half interim 2024 results presentation

23/08/2024 - 09:36

Oslo, Norway, 23 August 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2024 interim report on Wednesday 28 August 2024, 08:30am – 09:00am CEST (local time). The presentation [...]

Vistin Pharma ASA: Second quarter and first half 2024 financial results

23/08/2024 - 07:40

Oslo, Norway, 23 rd of August 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2024. Revenue in the second quarter ended at MNOK 106 compared to MNOK 107 in Q2 2023. Sales [...]

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

23/08/2024 - 07:00

Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared [...]

Burning Rock Reports Second Quarter 2024 Financial Results

23/08/2024 - 05:59

GUANGZHOU, China, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) [...]

Brains Bioceutical s’apprête à obtenir l’une des premières certifications CEP pour le cannabidiol au monde auprès de la Direction européenne de la qualité du médicament et soins de santé

23/08/2024 - 04:06

Faire progresser l’innovation pharmaceutique : la certification CEP de Brains Bioceutical permettra de simplifier le développement de médicaments à base de cannabinoïdes, en s’inspirant du médicament contre l’épilepsie [...]